Financial Survey: TherapeuticsMD (TXMD) versus AbbVie (ABBV)
TherapeuticsMD (NASDAQ: TXMD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Valuation and Earnings
This table compares TherapeuticsMD and AbbVie’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|TherapeuticsMD||$18.26 million||55.20||-$88.99 million||($0.46)||-10.74|
|AbbVie||$26.71 billion||5.64||$11.57 billion||$4.07||23.22|
AbbVie has higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
71.6% of TherapeuticsMD shares are held by institutional investors. Comparatively, 68.4% of AbbVie shares are held by institutional investors. 23.9% of TherapeuticsMD shares are held by insiders. Comparatively, 0.2% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
TherapeuticsMD has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.7%. TherapeuticsMD does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 44 consecutive years.
This table compares TherapeuticsMD and AbbVie’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for TherapeuticsMD and AbbVie, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD presently has a consensus target price of $14.88, suggesting a potential upside of 201.11%. AbbVie has a consensus target price of $93.33, suggesting a potential downside of 1.25%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, equities research analysts plainly believe TherapeuticsMD is more favorable than AbbVie.
AbbVie beats TherapeuticsMD on 10 of the 16 factors compared between the two stocks.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
AbbVie Company Profile
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.